サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1571995

PEG化タンパク質の世界市場

PEGylated Proteins

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
PEG化タンパク質の世界市場
出版日: 2024年10月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

PEG化タンパク質の世界市場は2030年までに20億米ドルに達する見込み

2023年に11億米ドルと推定されるPEG化タンパク質の世界市場は、分析期間2023-2030年にCAGR 9.1%で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPEG化タンパク質消耗品は、CAGR 8.5%を記録し、分析期間終了までに13億米ドルに達すると予想されます。PEG化タンパク質サービス分野の成長は、分析期間中CAGR 10.5%と推定されます。

米国市場は2億9,490万米ドルと推定され、中国はCAGR 8.5％で成長すると予測される

米国のPEG化タンパク質市場は、2023年に2億9,490万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億630万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.8%と8.0%と予測されています。欧州では、ドイツがCAGR 7.2%で成長すると予測されています。

世界のPEG化タンパク質市場- 主要動向と促進要因まとめ

技術の進歩はどのようにPEG化タンパク質の発展を促進しているか？

タンパク質にポリエチレングリコール（PEG）鎖を結合させるPEG化タンパク質は、生物製剤の薬物動態と治療効果を改善する能力があるため、バイオ医薬品開発においてますます重要になってきています。タンパク質工学とPEG化技術の進歩により、タンパク質をより精密かつ制御された形で修飾することが可能となり、治療用タンパク質の安定性の向上、免疫原性の低減、溶解性の向上につながっています。このような技術革新により、PEG化タンパク質は血流中での循環時間を長くすることが可能となり、投与回数を減らし、患者のコンプライアンスを向上させることができます。最近の動向には、部位特異的PEG化技術の創出も含まれます。これは、PEG分子がタンパク質の所定の位置に確実に結合し、タンパク質の生物学的活性を維持するものです。さらに、PEG化化学の進歩により、PEG化酵素、ペプチド、抗体の有効性が改善され、腫瘍学、免疫学、血液学など、さまざまな治療領域でより多用途に応用できるようになっています。これらのブレークスルーは、医薬品開発を前進させるだけでなく、生物製剤による治療を受けている患者の治療成績をも向上させています。

なぜPEG化タンパク質はバイオ医薬品で需要が高いのでしょうか？

PEG化タンパク質の需要は、主にタンパク質ベースの治療薬に関連する多くの課題を克服する能力により、バイオ医薬品分野で急速に高まっています。PEG化の主な利点の一つは、タンパク質の免疫原性を低下させ、免疫系に認識されにくく、破壊されにくくする能力です。この特性は、タンパク質治療薬の安全性と有効性を高めるため、バイオ医薬品の開発において特に価値が高いです。また、PEG化タンパク質は体内の酵素による分解にも強く、半減期が大幅に延びるため、投与回数を減らし、患者のアドヒアランスを向上させることができます。これは、長期的な治療を必要とする慢性疾患にとって特に有益です。さらに、PEG化タンパク質は、標的を絞ったドラッグデリバリーにおいても大きな可能性を示しており、標的外効果を最小限に抑えながら、特定の組織や細胞に治療用タンパク質を正確に送達することを可能にしています。長時間作用し、効果的で、患者に優しい生物製剤への需要が高まり続ける中、PEG化タンパク質は次世代治療の重要な構成要素として台頭してきています。

ヘルスケアと規制基準の変化は、PEG化タンパク質市場にどのような影響を与えていますか？

ヘルスケアの動向の変化、特に個別化医療と標的治療への重点の高まりは、PEG化タンパク質の採用に大きな影響を与えています。生物学的製剤が主要な治療薬として台頭する中、安全性と有効性を高めつつ、個々の患者のニーズに合わせた治療に対する需要が高まっています。PEG化タンパク質は、カスタマイズ可能な薬物動態と副作用プロファイルの低減により、個別化医療の原則に合致しています。さらに、規制状況はPEG化タンパク質市場の形成に重要な役割を果たしています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、臨床的有効性と免疫原性リスクの低減の両方を実証する生物製剤の承認に注力しており、PEG化は医薬品開発者にとって魅力的な戦略となっています。バイオシミラー、特にPEG化バイオシミラーの需要も増加傾向にあり、市場拡大の新たな機会を提供しています。ヘルスケアシステムが価値ベースの医療をますます優先するようになる中、PEG化タンパク質は安全で効果的かつ長時間作用する生物製剤のニーズに合致した革新的なソリューションを提供しています。

PEG化タンパク質市場の成長を促進する要因は？

PEG化タンパク質市場の成長は、技術の進歩、生物製剤の需要増加、患者中心のケアモデルへのシフトなど、いくつかの要因によってもたらされます。主な原動力の一つは、がん、自己免疫疾患、糖尿病などの慢性疾患の有病率の増加であり、これらはタンパク質ベースの治療による長期的な治療を必要とします。PEG化タンパク質は、半減期の延長と有効性の向上をもたらし、頻繁な投与の必要性を減らし、患者のアドヒアランスを向上させます。部位特異的PEG化および放出制御メカニズムの技術的進歩も市場を後押ししており、より正確な治療成果を可能にしています。さらに、バイオ医薬品業界がバイオシミラーの開発に力を入れるようになっていることも、PEG化タンパク質の需要を促進しています。生物製剤やバイオシミラーの開発に対する規制当局の支援は、ヘルスケア支出の増加と相まって、市場の成長をさらに後押ししています。ヘルスケアプロバイダーと製薬会社がより効果的で患者に優しい治療法の開発を目指す中、PEG化タンパク質は生物学的製剤治療の進歩に重要な役割を果たす態勢を整えています。

調査対象企業の例（全46件）

  • BIA Separations d.o.o.
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13899

Global PEGylated Proteins Market to Reach US$2.0 Billion by 2030

The global market for PEGylated Proteins estimated at US$1.1 Billion in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. PEGylated Protein Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the PEGylated Protein Services segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$294.9 Million While China is Forecast to Grow at 8.5% CAGR

The PEGylated Proteins market in the U.S. is estimated at US$294.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global PEGylated Proteins Market – Key Trends & Drivers Summarized

How Are Technological Advancements Enhancing the Development of PEGylated Proteins?

PEGylated proteins, which involve the attachment of polyethylene glycol (PEG) chains to proteins, have become increasingly important in biopharmaceutical development due to their ability to improve the pharmacokinetics and therapeutic efficacy of biologics. Advances in protein engineering and PEGylation technologies are enabling more precise and controlled modification of proteins, leading to improved stability, reduced immunogenicity, and enhanced solubility of therapeutic proteins. These technological innovations allow PEGylated proteins to have prolonged circulation times in the bloodstream, thereby reducing the frequency of dosing and improving patient compliance. Recent developments also include the creation of site-specific PEGylation techniques, which ensure that the PEG molecule attaches to a predetermined location on the protein, preserving the protein’s biological activity. Additionally, advances in PEGylation chemistry are improving the efficacy of PEGylated enzymes, peptides, and antibodies, making them more versatile and applicable across various therapeutic areas, including oncology, immunology, and hematology. These breakthroughs are not only advancing drug development but are also improving the therapeutic outcomes for patients undergoing treatment with biologics.

Why Are PEGylated Proteins in High Demand Across Biopharmaceuticals?

The demand for PEGylated proteins is rapidly increasing within the biopharmaceutical sector, primarily due to their ability to overcome many of the challenges associated with protein-based therapeutics. One of the key benefits of PEGylation is its ability to reduce the immunogenicity of proteins, making them less likely to be recognized and destroyed by the immune system. This property is particularly valuable in the development of biopharmaceuticals, as it enhances the safety and efficacy of protein therapeutics. PEGylated proteins are also more resistant to degradation by enzymes in the body, which significantly extends their half-life, allowing for reduced dosing frequencies and improved patient adherence. This is especially beneficial for chronic conditions that require long-term treatment. Furthermore, PEGylated proteins have shown considerable promise in targeted drug delivery, enabling precise delivery of therapeutic proteins to specific tissues or cells while minimizing off-target effects. As the demand for long-acting, effective, and patient-friendly biologics continues to grow, PEGylated proteins are emerging as a key component of next-generation therapies.

How Are Shifts in Healthcare and Regulatory Standards Impacting the PEGylated Proteins Market?

Shifting trends in healthcare, particularly the growing emphasis on personalized medicine and targeted therapies, are significantly influencing the adoption of PEGylated proteins. With the rise of biologics as a leading class of therapeutics, there is increasing demand for treatments that can be tailored to individual patient needs while offering enhanced safety and efficacy. PEGylated proteins, with their customizable pharmacokinetics and reduced side-effect profiles, align well with the principles of personalized medicine. Additionally, the regulatory landscape is playing a crucial role in shaping the PEGylated proteins market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are focusing on approving biologics that demonstrate both clinical efficacy and reduced immunogenic risks, making PEGylation an attractive strategy for drug developers. The demand for biosimilars, particularly PEGylated biosimilars, is also on the rise, providing new opportunities for market expansion. As healthcare systems increasingly prioritize value-based care, PEGylated proteins offer an innovative solution that aligns with the need for safe, effective, and long-acting biologics.

What Factors Are Driving Growth in the PEGylated Proteins Market?

The growth in the PEGylated proteins market is driven by several factors, including technological advancements, rising demand for biologics, and the shift toward patient-centric care models. One of the primary drivers is the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which require long-term treatment with protein-based therapies. PEGylated proteins offer extended half-lives and improved efficacy, reducing the need for frequent dosing and improving patient adherence. Technological advancements in site-specific PEGylation and controlled-release mechanisms are also propelling the market, enabling more precise therapeutic outcomes. Additionally, the biopharmaceutical industry's growing focus on developing biosimilars is driving demand for PEGylated proteins, as they offer a cost-effective alternative to branded biologics with comparable efficacy. Regulatory support for the development of biologics and biosimilars, coupled with increasing healthcare spending, is further boosting market growth. As healthcare providers and pharmaceutical companies seek to develop more effective and patient-friendly treatments, PEGylated proteins are poised to play a critical role in advancing biologic therapies.

Select Competitors (Total 46 Featured) -

  • BIA Separations d.o.o.
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • PEGylated Proteins - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biopharmaceuticals Drives Growth in the PEGylated Proteins Market
    • Technological Advancements in PEGylation Processes Enhance the Stability and Efficacy of Biologic Drugs
    • Increasing Use of PEGylated Proteins in Cancer Treatment Expands Opportunities in Oncology
    • Growing Adoption of PEGylated Therapeutics in Rare Disease Treatment Strengthens Market Growth
    • Rising Focus on Prolonging Drug Half-Life Drives Demand for PEGylated Proteins in Drug Delivery Systems
    • Advancements in Site-Specific PEGylation Techniques Enhance Precision and Effectiveness of Therapeutics
    • Growing Applications of PEGylated Proteins in Immunotherapy and Vaccines Expands Market Potential
    • Increased Use of PEGylated Enzymes in Metabolic Disorders Expands Opportunities in Enzyme Replacement Therapy
    • Rising Research and Development in Biotechnology Fuels Innovation in PEGylated Protein Therapeutics
    • Technological Integration of PEGylation with Monoclonal Antibodies Enhances Targeted Drug Delivery
    • Increasing Adoption of PEGylated Proteins in Chronic Disease Management Strengthens the Case for Long-Term Therapeutics
    • Growing Use of PEGylated Liposomes in Drug Formulations Expands Market for Advanced Drug Delivery Systems
    • Rising Focus on Reducing Immunogenicity in Protein Therapeutics Drives Growth in PEGylation Technologies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • JAPAN
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CHINA
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • EUROPE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • FRANCE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: France 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • GERMANY
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Germany 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Italy 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • UNITED KINGDOM
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: UK 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ASIA-PACIFIC
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Rest of World 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030

IV. COMPETITION